5-Aminolevulinic Acid Fluorescence in Detection of Peritoneal Metastases

  • Yonemura, Yutaka (NPO Organization to Support Peritoneal Dissemination Treatment) ;
  • Canbay, Emel (NPO Organization to Support Peritoneal Dissemination Treatment) ;
  • Ishibashi, Haruaki (NPO Organization to Support Peritoneal Dissemination Treatment) ;
  • Nishino, Eisei (Department of Pathology, Kishiwada Tokushukai Hospital) ;
  • Endou, Yoshio ;
  • Sako, Shouzou (NPO Organization to Support Peritoneal Dissemination Treatment) ;
  • Ogura, Shun-Ichirou (Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Central Research Resource Branch)
  • Published : 2016.06.01


Background: The value of 5-aminolevulinic acid (ALA) in fluorescence detection of peritoneal metastases and the underlying mechanisms were evaluated in patients with peritoneal surface malignancies. Materials and Methods: Oral 5-ALA was administered at a concentration of 20 mg/kg body weight with 50 ml of water 2 hours prior to surgery (n=115). The diagnostic value of 5-ALA based fluorescence production was evaluated following white light inspection during prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Then, peptide transporter PEPT1 (ALA influx transporter) and ATP-binding cassette transporter ABCG2 (porphyrin efflux transporter) gene expression was determined with quantitative real time (qRT)-PCR and pathological diagnoses confirmed for all tissue samples. Results: The 5-ALA based photodynamic detection rate was 17% for appendiceal mucinous neoplasms, 54% for colorectal cancers, 33% for gastric cancers, 67% for diffuse malign peritoneal mesotheliomas, and 89% for epithelial ovarian cancer of peritoneal metastases. 5-ALA was detected in all cases of peritoneal metastases originating from cholangiocarcinomas whereas it was not able to detect any in granulosa cell and gastrointestinal stromal tumor cases. Furthermore, PEPT1 was overexpressed whereas ABCG2 expression was downregulated in tumors detected with fluorescence. Conclusions: 5-ALA provided 100% specificity and high sensitivity to detect peritoneal metastases in subgroups of patients with peritoneal surface mailgnancies. ALA influx transporter PEPT1 and porphyrin efflux transporter ABCG2 genes are important in tumor specific 5-ALA induced fluorescence in vivo. Further studies should clarify diagnostic utility of 5-ALA in peritoneal surface malignancies.


  1. Ahmad S, Aboumarzouk O, Somani B, et al (2015). . Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. BJU Int, 110, 596-600
  2. Almerie MQ, Gossedge G, Wright KE, et al (2015). . Photodynamic diagnosis for detection of peritoneal carcinomatosis. J Surg Res, 195, 175-87
  3. Canbay E, Ishibashi H, Sako S, et al (2014). Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case. Surg Today, 44, 373-7
  4. Canis M, Botchorishvili R, Berreni N, et al (2001). 5-Aminolevulinic acid-induced (ALA). fluorescence for the laparoscopic diagnosis of peritoneal metastasis. AST An experimental study. Surg Endosc, 15, 1184-6
  5. Chu DZ, Lang NP, Thompson C, et al (2004). Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer, 63, 364-7
  6. Chua TC, Moran BJ, Sugarbaker PH, et al (2012). Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol, 30, 2449-56
  7. Daniltchenko DI, Riedl CR, Sachs MD, et al (2005). Longterm benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol, 174, 2129-33
  8. Denzinger S, Burger M, Walter B, et al (2007). Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8- year results of prospective randomized study. Urol, 69, 675-9
  9. Glehen O, Cotte E, Schreiber V, et al (2004). Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg, 91,747-54
  10. Glehen O, Gilly FN, Arvieux C, et al (2010). Association Francaise de Chirurgie Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol, 17, 2370-7
  11. Hagiya Y, Adachi T, Ogura S, An R, et al (2008). Nrf2- dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implicationsfor cancer cell response to photodynamic therapy. J ExpTher Oncol, 7, 153-67
  12. Hagiya Y, Endo Y, Yonemura Y, et al (2012). Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC). transporter ABCG2 in 5-aminolevulinic acid (ALA). -based photocytotoxicity of gastric cancer cells in vitro. Photodiagnosis Photodynamic Therapy, 9, 204-14.
  13. Jayne DG, Fook S, Loi C, et al (2002). Peritoneal carcinomatosis from colorectal cancer. Br J Surg, 89,1545-50
  14. Kishi K, Fujiwara Y, Yano M, et al (2012). Staging laparoscopy using ALA-mediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer. J Surg Oncol, 106, 294-8
  15. Krammer B and Plaetzer K. (2008). ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci, 7, 283-9
  16. Ladner DP, Steiner RA, Allemann J, et al (2001). Photodynamic diagnosis of breast tumors after oral application of aminolevulinic acid. Br J Cancer, 84, 33-7
  17. Loning M, Diddens H, Kupker W, et al (2004). Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer, 100, 1650-6
  18. Orth K, Russ D, Steiner R, et al (2000). Fluorescence detection of small gastrointestinal tumours: Principles, technique, first clinical experience. Langenbecks Arch Surg, 385,488-94
  19. Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non- gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358-63.<358::AID-CNCR16>3.0.CO;2-O
  20. Stummer W, Pichlmeier U, Meinel T, et al (2006). ALAGlioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 7, 392-401
  21. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al (1989). Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol, 16, 83-97
  22. Sugarbaker PH (1998). Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol, 14, 254-61<254::AID-SSU10>3.0.CO;2-U
  23. Sugarbaker PH (2006). New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol, 7, 69-76
  24. Verwaal VJ, Bruin S, Boot H, et al (2008). 8-year followup of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol, 15, 2426-32
  25. Yan TD, Brun EA, Cerruto CA, et al (2007). Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol, 14, 41-9
  26. Yan TD, Deraco M, Baratti D, et al(2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peri toneal mesothelioma: multi-institutional experience. J Clin Oncol, 27, 6237-42
  27. Yang XJ, Huang CQ, Suo T, et al (2011). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol, 18, 1575-81
  28. Zopf T, Schneider AR, Weickert U, et al (2005). Improved preoperative tumor staging by 5-aminolevulinic acid induced fluorescence laparoscopy. Gastrointest Endosc, 62,763-7

Cited by

  1. Image-guided surgery in gynecologic oncology vol.13, pp.26, 2017,
  2. Photodynamic Detection of Peritoneal Metastases Using 5-Aminolevulinic Acid (ALA) vol.9, pp.3, 2017,